Format

Send to

Choose Destination
EMBO Mol Med. 2016 May 2;8(5):439-41. doi: 10.15252/emmm.201606325. Print 2016 May.

Successful correction of hemophilia by CRISPR/Cas9 genome editing in vivo: delivery vector and immune responses are the key to success.

Author information

1
INSERM, UMR 1064-Center for Research in Transplantation and Immunology, Nantes, France ITUN, CHU Nantes, Nantes, France Faculté de Médecine, Université de Nantes, Nantes, France.
PMID:
27138565
PMCID:
PMC5130315
DOI:
10.15252/emmm.201606325
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for HighWire Icon for PubMed Central
Loading ...
Support Center